In vitro laboratory models of proliferative vitreoretinopathy

• Published in: Survey of ophthalmology 2023-09, Vol.68 (5), p.861-874
• Main Authors: Gao, Ashley Y., Haak, Andrew J., Bakri, Sophie J.
• Format: Article
• Language: English
• Subjects: Animal; Cell culture; Chip; Eye; Humans; Hydrogel; Membrane; Organoid; Proliferative vitreoretinopathy; Retina; Retinal cell culture; Retinal Detachment; Vitreoretinopathy, Proliferative - drug therapy; Vitreoretinopathy, Proliferative - metabolism; Vitreous
• ISSN: 0039-6257; 1879-3304
• DOI: 10.1016/j.survophthal.2023.05.007

Proliferative vitreoretinopathy (PVR), the most common cause of recurrent retinal detachment, is characterized by the formation and contraction of fibrotic membranes on the surface of the retina. There are no Food and Drug Administration (FDA)-approved drugs to prevent or treat PVR. Therefore, it is necessary to develop accurate in vitro models of the disease that will enable researchers to screen drug candidates and prioritize the most promising candidates for clinical studies. We provide a summary of recent in vitro PVR models, as well as avenues for model improvement. Several in vitro PVR models were identified, including various types of cell cultures. Additionally, novel techniques that have not been used to model PVR were identified, including organoids, hydrogels, and organ-on-a-chip models. Novel ideas for improving in vitro PVR models are highlighted. Researchers may consult this review to help design in vitro models of PVR, which will aid in the development of therapies to treat the disease.